Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)
Conditions
- Recurrent/Metastatic Gastric Cancer
Interventions
- DRUG: Trastuzumab + Ramucirumab + Paclitaxel
Sponsor
Yonsei University